Faina Nakhlis1,2, Fisher D Katlin3,4, Samantha C Grossmith3,4, Ashley DiPasquale3,4,5, Beth T Harrison6, Stuart J Schnitt6, Tari A King3,4. 1. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. fnakhlis@partners.org. 2. Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. fnakhlis@partners.org. 3. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. 4. Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. 5. Harvard T.H. Chan School of Public Health, Boston, MA, USA. 6. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Non-classic lobular carcinoma in situ (NC-LCIS) represents a spectrum of lesions, histologically distinct from classic LCIS (C-LCIS) and ductal carcinoma in situ (DCIS). Several studies have reported on the safety of breast conservation (BCS) in patients with DCIS or invasive breast cancer and concomitant C-LCIS, yet there are no data addressing this question for patients with concomitant NC-LCIS. We evaluated local recurrence (LR) after BCS in patients with DCIS or invasive cancer and concomitant NC-LCIS. PATIENTS AND METHODS: We searched institutional databases using natural language processing to identify patients with DCIS or invasive breast cancer and concomitant NC-LCIS treated with BCS between 2000 and 2015. Charts were reviewed to collect demographics, disease and treatment details, and recurrence events. All results represent descriptive analyses. RESULTS: We identified 71 patients with DCIS (n = 13) or invasive cancer (n = 58) and concomitant NC-LCIS treated with BCS. Median patient age was 59 years (33-77 years), and median invasive tumor size was 1.2 cm (0.1-6.9 cm); 62% of DCIS and 79% of invasive cancer patients had hormone receptor (HR)-positive disease. Among DCIS patients, seven (54%) received radiation and none hormonal therapy. Among those with invasive cancer, 52 (90%) received radiation, 17 (29%) received chemotherapy and 44 of 55 with HR-positive disease (78%) received hormonal therapy. At median follow-up of 79 months (1-265 months), the LR rate was 8% and 2% among patients with DCIS and invasive cancer, respectively. CONCLUSION: NC-LCIS is rarely present in association with DCIS or invasive cancer, and it does not appear to impact LR outcomes following BCS.
BACKGROUND: Non-classic lobular carcinoma in situ (NC-LCIS) represents a spectrum of lesions, histologically distinct from classic LCIS (C-LCIS) and ductal carcinoma in situ (DCIS). Several studies have reported on the safety of breast conservation (BCS) in patients with DCIS or invasive breast cancer and concomitant C-LCIS, yet there are no data addressing this question for patients with concomitant NC-LCIS. We evaluated local recurrence (LR) after BCS in patients with DCIS or invasive cancer and concomitant NC-LCIS. PATIENTS AND METHODS: We searched institutional databases using natural language processing to identify patients with DCIS or invasive breast cancer and concomitant NC-LCIS treated with BCS between 2000 and 2015. Charts were reviewed to collect demographics, disease and treatment details, and recurrence events. All results represent descriptive analyses. RESULTS: We identified 71 patients with DCIS (n = 13) or invasive cancer (n = 58) and concomitant NC-LCIS treated with BCS. Median patient age was 59 years (33-77 years), and median invasive tumor size was 1.2 cm (0.1-6.9 cm); 62% of DCIS and 79% of invasive cancer patients had hormone receptor (HR)-positive disease. Among DCIS patients, seven (54%) received radiation and none hormonal therapy. Among those with invasive cancer, 52 (90%) received radiation, 17 (29%) received chemotherapy and 44 of 55 with HR-positive disease (78%) received hormonal therapy. At median follow-up of 79 months (1-265 months), the LR rate was 8% and 2% among patients with DCIS and invasive cancer, respectively. CONCLUSION: NC-LCIS is rarely present in association with DCIS or invasive cancer, and it does not appear to impact LR outcomes following BCS.
Authors: Beth T Harrison; Faina Nakhlis; Deborah A Dillon; T Rinda Soong; Elizabeth P Garcia; Stuart J Schnitt; Tari A King Journal: Mod Pathol Date: 2020-01-13 Impact factor: 7.842
Authors: Tari A King; Melissa Pilewskie; Shirin Muhsen; Sujata Patil; Starr K Mautner; Anna Park; Sabine Oskar; Elena Guerini-Rocco; Camilla Boafo; Jessica C Gooch; Marina De Brot; Jorge S Reis-Filho; Mary Morrogh; Victor P Andrade; Rita A Sakr; Monica Morrow Journal: J Clin Oncol Date: 2015-09-14 Impact factor: 44.544
Authors: Alison Laws; Fisher Katlin; Faina Nakhlis; Sona A Chikarmane; Stuart J Schnitt; Tari A King Journal: Ann Surg Oncol Date: 2021-09-23 Impact factor: 5.344
Authors: Melissa P Murray; Chad Luedtke; Laura Liberman; Tatjana Nehhozina; Muzaffar Akram; Edi Brogi Journal: Cancer Date: 2012-11-06 Impact factor: 6.860
Authors: Faina Nakhlis; Beth T Harrison; Catherine S Giess; Susan C Lester; Kevin S Hughes; Suzanne B Coopey; Tari A King Journal: Ann Surg Oncol Date: 2018-10-25 Impact factor: 5.344